Q-linea announces strong support of the TO1 warrant program as well as an extension of existing loan from large shareholder
16 april, 09:58
Q-linea AB (publ) (“Q-linea” or the “Company”) (Nasdaq Stockholm: QLINEA) today announces that holders representing approximately 61 percent of the total number of outstanding warrants have expressed their support and intention to exercise all of their warrants during the TO1 exercise period.
Shareholders including Ulf Landegren (Landegren Gene Technology AB), Investment AB Öresund, Transferator AB and Fjärde AP-fonden, representing approximately 61 percent of the outstanding warrants, have expressed their intention to exercise all of their TO1 warrants during the exercise period 5 – 19 May 2025.
Q-linea and Nexttobe AB has also agreed to extend the existing loan of SEK 40.5 million with one year to 30 June 2027. The extension will be addressed at the upcoming annual general meeting, scheduled to be held on June 26 2025.
“We are pleased to see the continued strong support from our main owners as we continue our journey towards profitability” said Stuart Gander, President and CEO of Q-linea.
For more information, please contact:
Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463
Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20
About Q-linea
Q-linea’s rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.
Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.
ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com
This information is information that Q-linea is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-16 09:58 CEST.
Attachments
Ämnen i artikeln
Q-linea announces strong support of the TO1 warrant program as well as an extension of existing loan from large shareholder
16 april, 09:58
Q-linea AB (publ) (“Q-linea” or the “Company”) (Nasdaq Stockholm: QLINEA) today announces that holders representing approximately 61 percent of the total number of outstanding warrants have expressed their support and intention to exercise all of their warrants during the TO1 exercise period.
Shareholders including Ulf Landegren (Landegren Gene Technology AB), Investment AB Öresund, Transferator AB and Fjärde AP-fonden, representing approximately 61 percent of the outstanding warrants, have expressed their intention to exercise all of their TO1 warrants during the exercise period 5 – 19 May 2025.
Q-linea and Nexttobe AB has also agreed to extend the existing loan of SEK 40.5 million with one year to 30 June 2027. The extension will be addressed at the upcoming annual general meeting, scheduled to be held on June 26 2025.
“We are pleased to see the continued strong support from our main owners as we continue our journey towards profitability” said Stuart Gander, President and CEO of Q-linea.
For more information, please contact:
Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463
Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20
About Q-linea
Q-linea’s rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.
Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.
ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com
This information is information that Q-linea is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-16 09:58 CEST.
Attachments
Ämnen i artikeln
SBB
Fonder
-160x160.jpg&w=3840&q=75)
Inflation
Analys
-992x558.png&w=3840&q=75)
-992x558.jpg&w=3840&q=75)
-992x558.jpg&w=3840&q=75)
Stenbeck-comebacken
SBB
Fonder
Mest läst
Inflation
Analys
Stenbeck-comebacken
Senaste nytt
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
